Christine C. Roberts
Kolon Life Science (South Korea)(KR)
Publications by Year
Research Areas
Cervical Cancer and HPV Research, Hepatitis B Virus Studies, SARS-CoV-2 and COVID-19 Research, Genital Health and Disease, Immunotherapy and Immune Responses
Most-Cited Works
- → The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years(2009)627 cited
- → Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women(2010)562 cited
- → Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial(2017)452 cited
- → A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions(2009)327 cited
- → Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial(2019)318 cited
- → The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years(2009)241 cited
- → HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine(2008)196 cited
- → Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers(2019)120 cited
- → Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types(2014)73 cited
- → Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults(2018)67 cited